Search clinical trials for: RUXOLITINIB

Total 381 results

University of Zurich
Incyte Corporation

Not yet recruiting

Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities (TRUX-LST)

Exanthema | Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
Ryvu Therapeutics SA

Not yet recruiting

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Myelofibrosis

Italy, Poland
Incyte Corporation

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host-disease
Hematology department of the 920th hospital

Recruiting

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

Severe Aplastic Anemia

China
Peking University People's Hospital

Not yet recruiting

Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

cGVHD
M.D. Anderson Cancer Center
Incyte Corporation

Not yet recruiting

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Myelofibrosis | Splenomegaly

United States
Clinical Research Centre, Malaysia

Not yet recruiting

Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia (EVOS)

Staphylococcus Aureus Bacteremia

Malaysia
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
Fundación Oftalmológica de Santander Clínica Carlos...
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS

Not yet recruiting

Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment (GvHD)

Graft Versus Host Disease
University of Chicago

Not yet recruiting

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN)

Myeloproliferative Neoplasms

United States
Innovaderm Research Inc.

Recruiting

Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects With Discoid Lupus Erythematosus

Discoid Lupus Erythematosus

Canada
Incyte Corporation

Recruiting

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population (OPERA-1)

Pregnancy Related | Atopic Dermatitis

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Real-world Ruxolitinib Experience in PV (REVIEW)

Polycythemia Vera
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit (JAKAHDI)

Hemophagocytic Syndromes
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis (TRuE-AD4)

Atopic Dermatitis

Germany, Poland, United States, Spain, United Kingdom, Italy, Belgium, Canada, Netherlands, Australia, Bulgaria, France, Switzerland, Hungary, Korea, Republic of
Stefanie Sarantopoulos, MD, PhD.
National Institutes of Health (NIH); Incyte Corporation; Rigel Pharmaceuticals

Not yet recruiting

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Chronic Graft Versus Host Disease

United States
Oncotherapeutics

Not yet recruiting

A Trial of Selinexor, Ruxolitinib and Methylprednisolone (KPT-IST-391)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Incyte Corporation

Recruiting

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Prurigo Nodularis

United States
Oncotherapeutics
Incyte Corporation

Not yet recruiting

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Multiple Myeloma
Federal Research Institute of Pediatric Hematology...

Recruiting

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Inborn Errors of Immunity

Russian Federation
University of California, San Francisco
Incyte Corporation

Not yet recruiting

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Hemophagocytic Lymphohistiocytoses

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia

Poland, Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain, Italy, Netherlands
Sichuan University

Not yet recruiting

MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

GVHD | Acute Stem Cell Transplant Complications

China
Washington University School of Medicine
Incyte Corporation

Recruiting

Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Graft Versus Host Disease | Graft Vs Host Disease | Graft-versus-host-disease

United States
Baylor Research Institute

Not yet recruiting

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Breast Cancer | Metastatic Triple-Negative Breast Carcinoma

United States
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Severe Aplastic Anemia | Single Lineage Cytopenias, T-LGL | Hypoplastic MDS

United States
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease

Kohlmeier Degos Disease With Neurologic Involvement

United States
Karyopharm Therapeutics Inc

Not yet recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (SENTRY-2)

Myelofibrosis | Moderate Thrombocytopenia
Malaria Consortium

Recruiting

Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso (BF-IPTsc)

Malaria

Burkina Faso
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Ruxolitinib as GVHD Prophylaxis in AA Patients

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Peking Union Medical College Hospital

Recruiting

The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia

Severe Checkpoint Inhibitor Pneumonitis

China
Centre Hospitalier Universitaire de Nice

Recruiting

Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas (PREVENT)

Vitiligo

France
Institute of Hematology & Blood Diseases Hospital

Recruiting

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (PV)

Polycythemia Vera

China
The First Affiliated Hospital with Nanjing Medical...
Jiangbin Hospital Affiliated to Jiangsu University; Nanjing Second Hospital; Jiangning...

Recruiting

Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

MDS/MPN

China
Assiut University

Not yet recruiting

Ruxolitinib in Patients With Myelofibrosis

Myelofibrosis
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN2)

Prurigo Nodularis

Korea, Republic of, Spain, United States, Poland, Italy, Australia, Austria, Germany, Canada, Switzerland, France, Denmark, Bulgaria
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) (R-HLH)

Haemophagocytic Lymphohistiocytosis
Incyte Corporation

Recruiting

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN1)

Prurigo

United States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; Incyte Corporation

Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Myelofibrosis Due to and Following Polycythemia Vera

United States
Incyte Corporation

Recruiting

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (MORPHEUS)

Atopic Dermatitis

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Myelofibrosis

Austria
Medical College of Wisconsin

Recruiting

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Graft-versus-host Disease

United States
Novartis Pharmaceuticals

Recruiting

A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

Graft-versus-Host Disease

Korea, Republic of
Institute of Hematology & Blood Diseases Hospital

Recruiting

Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Transplant-Related Disorder

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

Transplant-Related Disorder

China
John Reneau

Recruiting

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

T-Cell Large Granular Lymphocyte Leukemia

United States
St. Jude Children's Research Hospital

Recruiting

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Hematologic Malignancy | Myeloid Malignancy

United States

Search clinical trials for: RUXOLITINIB

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations